Progenics Pharma (PGNX) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2015 Financial and Business Results
March 11, 2016 8:00 AM ESTRELISTOR® Net Sales Increased to $23.0 Million for the Fourth Quarter Oral RELISTOR Remains On-track for April 19, 2016 PDUFASubcutaneous RELISTOR Approved in Europe for All Opioid-Induced ConstipationAZEDRA® Ultra-Orphan Cancer Therapeutic Receives FDA Breakthrough DesignationAZEDRA Completes Enrollment of 68 Patients in Pivotal Trial and Topline Results Expected Between December 2016 and March 2017Initiated Pivotal Phase 3 Study of 1404, PSMA-Targeted SPECT/CT Imaging Agent Clinical Studies Planned for PyL PSMA-Targeted PET/CT Imaging Agent Licensed... More
